Evaluation of the efficacy of sofosbuvir/velpatasvir and ribavirin in Japanese hepatitis C patients who failed direct-acting antiviral agents: a prospective study in real life settings.

Evaluation of the efficacy of sofosbuvir/velpatasvir and ribavirin in Japanese hepatitis C patients who failed direct-acting antiviral agents: a prospective study in real life settings. - The efficacy of sofosbuvir/velpatasvir and ribavirin in Japanese hepatitis C patients who failed direct-acting antiviral agents.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035713

Enrollment

150

Registered

2019-03-01

Start date

2019-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhotic and non cirrhotic patients with hepatitis C virus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: chronic hepatitis C and compensated cirrhotic patients with HCV RNA

Exclusion criteria

Exclusion criteria: decompensated cirrhosis severe anemia

Design outcomes

Primary

Measure	Time frame
sustained virological response (SVR) at 12 weeks after the end of treatment (EOT)	—

Secondary

Measure	Time frame
SVR at 24 weeks after the EOT incidence rate of adverse events during treatment	—

Countries

Japan

Contacts

Public ContactHitomi Sezaki

Toranomon Hospital hepatology

hitomis@mx1.harmonix.ne.jp03-3588-1111

Outcome results